ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IDHC Integrated Diagnostics Holdings Plc

0.32
-0.0005 (-0.16%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Integrated Diagnostics Holdings Plc IDHC London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.0005 -0.16% 0.32 12:15:00
Open Price Low Price High Price Close Price Previous Close
0.32 0.32 0.32 0.3205
more quote information »

Integrated Diagnostics IDHC Dividends History

No dividends issued between 20 May 2014 and 20 May 2024

Top Dividend Posts

Top Posts
Posted at 06/12/2022 14:41 by brucie5
Finally - (and then I'll stop!) I notice that IDHC was included in Mark Simpson's 40 stock folio for income investing, back on October 26. Important to stress it's a highly diversified folio, so can afford some geographically specific headwinds - no doubt the case with IDHC.



He used this screen to generate the folio:

Market Cap > £150m.
TTM Earnings Yield, Rank in Market > 60%
TTM Dividend Yield, Rank in Industry Group > 60%
1-Year Rolling Dividend Yield, Rank in Industry Group > 60%
Net Gearing, including Pension < 50%

This portfolio is forecast to yield 7.2%, and 17 of the constituents have bought back shares within the last month. This is a very reasonable income from a (hopefully) well-protected portfolio.

Note: Though yielding above average for his folio, IDHC did not satisfy this last bit about director buy-backs, though as stated in previous posts, the CEO has a very high level of share ownership already!
Posted at 06/12/2022 13:13 by brucie5
REWARDS
Trading at 75.8% below our estimate of its fair value

Earnings are forecast to grow 21.67% per year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 30.3%

RISK ANALYSIS
Dividend of 12.97% is not well covered by earnings or cash flows

High level of non-cash earnings

Profit margins (16.8%) are lower than last year (27.8%)
Posted at 06/12/2022 13:09 by brucie5
Hmm. Large buy reported here: wonder if it's the boss' investment proxy hoovering up off the floor again. She owns c. 26% of the company, I believe.

06-Dec-22 12:45:55 0.686 300,000 Buy* 0.672 0.70 205.80k

This link is quite interesting in showing who the buyers/sellers have been over last months.
Posted at 06/12/2022 08:39 by brucie5
I may have made a mistake by holding, nevermind adding here. But I do notice that the dividend was paid in full to small investors over the summer, at at 8.6% current, it's still an income stock. But also the ROE, ROC and operating margin are all top in their sector. So a nifty business, with severe currency headwinds.
Posted at 05/12/2022 11:10 by brucie5
Noone passed comment on these. Thorpematt, do you still hold?
Business on the ground appears to be doing well, though depreciation of the EGP.

3(rd) Quarter Results

Thursday, 17 November 2022

Integrated Diagnostics Holdings Plc reports sustained growth in non-Covid offering showcasing the fundamental strength and potential of the business

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, released today its reviewed financial statements and operational performance for the nine-month period ended 30 September 2022, reporting revenue (compliant with IFRS) of EGP 2.8 billion. In line with the trend seen earlier in the year, IDH's conventional business (which includes IDH's full service roster excluding Covid-19-related tests) continued to showcase its underlying strength and potential, delivering a solid 14% year-on-year expansion, partially offsetting the expected decline in Covid-19-related(1) revenues for the nine-month period. Growth at IDH's conventional business (which made up 76% of total revenues) was supported by a solid 7% increase in test volumes, testament to the robust underlying demand for the Company's conventional test portfolio. Likewise, on a quarterly basis, conventional revenues expanded 17% year-on-year and 12% quarter-on-quarter in Q3 2022, making it the strongest three-month period performance ever recorded by the Group's conventional offering. Meanwhile, consolidated revenue for the third quarter stood at EGP 846 million, with the Group recording a net loss of EGP 36 million in Q3 2022. It is important to note that controlling for the losses resulting from transactions completed by the Company to secure the USD balance needed to fulfil its FY2021 dividend obligations to shareholders, the Group would have recorded a net profit of EGP 544 million in 9M 2022 and EGP 105 million in Q3 2022.
Posted at 07/9/2022 11:49 by brucie5
I may have misread it but...
Posted at 01/8/2022 11:34 by brucie5
Can't complain about dividend received, though.
Posted at 27/7/2022 17:51 by brucie5
Interesting RNS. How worried should we be? Share price hasn't responded at all, so the company appears to have reassured.

"Since the recommendation of the final dividend by IDH's board of directors and the subsequent declaration of the dividend by IDH's shareholders, the macro-economic situation globally and in Egypt has changed significantly. As such, despite its financial rigour and planning outlined above, IDH has encountered significant difficulties in sourcing the required amounts of USD to exchange for EGP for the purposes of making the Dividend Payment. This is largely as a consequence of the deteriorating broader macro-economic situation, including inflationary pressures and other consequences arising from the conflict in Ukraine, which has led to a scarcity of USD available in the foreign exchange markets for conversion to EGP.

2. Payment in full of dividend to minority shareholders today

Despite the above-mentioned challenges, IDH has sourced sufficient USD to cover the full Dividend Payment due to all shareholders with the exception of its two largest shareholders, Hena Holdings Ltd ("Hena Holdings") and Actis IDH Limited ("Actis"), which have both agreed to defer their entitlement as described in section 3 of this release. IDH will begin paying the Dividend Payment due to all Eligible Shareholders (excluding Hena Holdings and Actis) as it falls due today (27 July 2022).

3. Deferral of dividend entitlement by IDH's two largest shareholders

In light of these aforementioned difficulties in the foreign exchange market, IDH's two largest shareholders, Hena Holdings and Actis (the "Deferring Shareholders"), have agreed with IDH to defer the payment of their pro rata share of the Dividend Payment (being USD 17.7 million for Hena Holdings and USD 14.6 million for Actis, respectively) from 27 July 2022 to 27 January 2023 (the "Hena/Actis Deferral").

It is IDH's intention to seek to repay the sums due to both Deferring Shareholders as soon as it is practicably able to source the required USD currency. At this time, the Company expects the repayment to take place within the coming two months."
Posted at 07/6/2022 12:15 by brucie5
Rare combi of dividend and quality. Obviously, with geographical risk, though this increasingly spread. I guess however, that Ukraine an wheat shortages may ad to tensions in its geographies.
Posted at 28/4/2022 10:08 by tomps2
IDHC pitched in the latest episode of Sell It To The City

Neil Cooper pitches Integrated Diagnostic Holdings (IDHC) to leading fund managers, Andy Brough, Judith MacKenzie and Stephen English at 25m47s in the latest PIWORLD Sell It To The city.

Watch the video here: www.piworld.co.uk/education-videos/sell-it-to-the-city-april-2022/

Or listen to the podcast here: piworld.podbean.com/e/sell-it-to-the-city-april-2022/

Your Recent History

Delayed Upgrade Clock